A carregar...
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine phosphate (EMP), 10 mg kg(-1), and intravenous epirubicin (EPR) infusions, 100 mg m(-2), every third week up to a cumulative dose of 500 mg m(-2). Biochemical response [>...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
1997
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2223802/ https://ncbi.nlm.nih.gov/pubmed/9218739 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|